Enanta Pharmaceuticals | ENTA - Operating Expenses


Enanta Pharmaceuticals reported $126.59M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 223.22M 10.86M Dec/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Biogen USD 1.96B 69.6M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 18.17B 8.01B Mar/2026
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026